Immunotherapy with programmed death 1 (PD-1) antibody pembrolizumab led to an objective response rate (ORR) of 14.6% in previously treated advanced cervical cancer patients with PD-L1–positive disease, as reported by Chung et al. on behalf of the KEYNOTE-158 investigators in the Journal of Clinical Oncology.
What is new in the treatment of gynaecological cancer including ovarian cancer, cervical cancer and endometrial cancer? Read our gynaecological cancer blog and learn more about the latest advancements in the treatment female cancers.
On 19 December 2018, the FDA approved olaparib (Lynparza®, AstraZeneca) as a maintenance treatment for adult advanced epithelial ovarian, fallopian tube or primary peritoneal cancer patients who achieving a complete or partial response to first-line platinum-based chemotherapy and who have deleterious germline or somatic BRCA-mutatations (gBRCAm or sBRCAm) by an FDA-aproved test or who are suspected to have deleterious BRCA-mutatations (BRCAm).
Adding ipilimumab (IPI [Yervoy®, Bristol-Myers Squibb]) to nivolumab (NIVO [Opdivo®, Bristol-Myers Squibb]) induction followed by maintenance with single-agent NIVO had a superior objective tumour response rate and progression-free survival (PFS) when compared to NIVO alone in patients with persistent or recurrent epithelial ovarian cancer.
Increased cancer awareness improves survival, according to a recent study by Cancer Research UK (CRUK) published in the British Journal of Cancer (BJC). The researchers matched cancer symptom awareness from a population-based survey in over 35,000 people across the UK with the cancer registry.
In women with stage IIIC or IV ovarian cancer, primary cytoreductive surgery (PCS) may be preferred when there is a high chance to achieve cytoreduction to <1 cm with acceptable morbidity. This was concluded by an expert panel who published clinical guidelines in the Journal of Clinical Oncology (JCO) this week.
There is no excerpt because this is a protected post.